BusinessAbeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive OfficerBy Nasdaq OMXApr 2, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business HighlightsBy Nasdaq OMXMar 16, 2018, 9:10 PM UTC
BusinessAbeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical TrialBy Nasdaq OMXFeb 7, 2018, 1:45 PM UTC
BusinessAbeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIABy Nasdaq OMXNov 9, 2017, 1:45 PM UTC
BusinessAbeona Therapeutics Announces Public Offering of Common StockBy Nasdaq OMXOct 16, 2017, 8:01 PM UTC
BusinessAbeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102By Nasdaq OMXSep 28, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
